Personalized decisions among the optimal strategy to reduce glucose levels should also account for the possible side effects of the glucose‐lowering medications, as some could increase the risk of hypoglycaemia (i.e. sulphonylureas and insulin) while others are neutral in this respect (DPP‐4i, GLP‐1RA, MF, TZD and SGLT‐2i). The gene discussed is INS; the disease is Hypoglycemia.